Quantcast

Latest Cephalon Inc. Stories

2014-06-23 12:29:37

BOCA RATON, Fla., June 23, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has filed an ANDA with a Paragraph IV certification for bendamustine hydrochloride powder for IV (infusion), 25 mg/vial and 100 mg/vial, a generic version of Treanda® by Cephalon, Inc. On May 27, 2014, Cephalon, Inc. filed a Paragraph IV lawsuit against Breckenridge and its development and manufacturing partner Natco Pharma Limited in the United States District Court for the...

2014-05-30 16:25:02

DUBLIN, May 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil(® )(armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil(®) is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or...

2014-03-07 20:22:28

COLUMBIA, S.C., March 7, 2014 /PRNewswire/ -- The South Carolina Court of Common Pleas, Fifth Judicial Circuit has issued a ruling that will allow the State of South Carolina to move forward with efforts to hold pharmaceutical giant, Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., accountable for overpayments by the State Health Plan and for violations of the South Carolina Unfair Trade Practices Act. The court on February 21, denied Cephalon's motion for summary...

2014-02-04 08:34:45

DUBLIN, Feb. 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. Actavis' ANDA product is a generic version of Cephalon's Treanda(®), a treatment for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Cephalon, Inc. filed suit against Actavis on January 31,...

2011-08-02 15:10:00

FRAZER, Pa., Aug. 2, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2011 net sales of $730.1 million, a 2 percent increase compared to net sales of $712.4 million for the second quarter of 2010. Basic income per common share for the period was $1.54 compared to $1.18 for the second quarter of 2010. Excluding amortization expense and certain other items, adjusted net income for the second quarter of 2011 was $142.6 million, a 14 percent decrease versus...

2011-07-21 08:30:00

FRAZER, Pa., July 21, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. Both products are indicated for the management of breakthrough pain in opioid-tolerant patients with cancer. Under this REMS, pharmacies and healthcare...

2011-07-14 10:06:00

FRAZER, Pa., July 14, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its stockholders voted to approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction remains under review by the U.S. Federal Trade Commission and the European Commission. Cephalon and Teva continue to operate as two independent companies pending those...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related